A University of Alabama at Birmingham Heersink School of Medicine-led study suggests that first-time transient ischemic ...
The following is a summary of “Association between impaired brachial flow-mediated dilation and early neurological ...
The following is a summary of “Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion,” published in the February ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...
9d
HealthDay on MSNASA: Alteplase Ups Outcomes at 4.5 to 24 Hours After Symptom Onset in Acute Ischemic StrokeFor patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated w ...
3d
TipRanks on MSNDiaMedica Therapeutics Appoints Daniel J. O’Connor to BoardAn update from Diamedica Therapeutics ( ($DMAC) ) is now available. On February 20, 2025, DiaMedica Therapeutics appointed Daniel J. O’Connor to ...
DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...
Leading Spanish neuroradiologists presented a unique multicentre registry to boost stroke treatment at the 12th Triángulo ...
Researchers found that the percentage of patients achieving a score of 0 or 1 on the modified Rankin scale at 90 days was 40.3 and 26.3% in the alteplase and standard medical treatment groups ...
In animal studies of acute stroke, bradykinin B2 receptor expression on brain endothelial cells in the ischemic region increased 36-fold. In this environment, newly generated bradykinin from DM199 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results